ABSTRACT
Following and correcting for these changes over the
course of treatment would allow for more accurate target
localization, and also a better understanding of how to
design margins for standard, static RT. Insufficient dose to
the cancer bearing area of the prostate (2) may occur if
target motion is ignored during treatment delivery. In
addition, real-time organ tracking allows for the calcula-
tion of the dose actually delivered to the target accounting
for any motion that was observed. Thus, dynamic dose
reconstruction would allow for fine-tuning of future frac-
tions to compensate for the influence of motion on
already-delivered fractions-adaptive RT (3).
